PTC Therapeutics, Inc. PTCT
Set alert
At close · Oct 30
After hours · Oct 30, 5:47 PM ET
- YTD
- -21.05%
- 1 year
- -11.95%
- Open
- 64.75
- Prev close
- 64.46
- Mkt cap
- 5.01B
- Vol
- 2.36M
- Avg vol
- 1.10M
- EPS
- -0.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 59.65
- High
- 65.34
- Forward P/E
- 25.30
- Beta
- 0.49
- Short ratio
- 6.38
- Inst. own
- 122.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 65.57
- 200-d avg
- 70.76
- 1y target
- 97.80
5D chart
Events in this range
- Oct 29, 2026Earnings: -0.62; estimate 0.1434; surprise -532.36%
- Oct 30, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
Signals (110)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:10 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
2 days ago prnewswire.com
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of…
-
2 days ago benzinga.com
TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95
TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.
-
2 days ago benzinga.com
RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.
-
2 days ago benzinga.com
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.
2 days ago seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com
PTC Therapeutics Q3 Earnings Call Highlights
PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to…
3 days ago zacks.com
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
3 days ago zacks.com
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.
3 days ago benzinga.com
PTC Therapeutics Q3 2026 Earnings Call Transcript
PTC Therapeutics (NASDAQ:PTCT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
-
3 days ago benzinga.com
CORRECTION: PTC Therapeutics Q3 Adj. EPS $0.94 Beats $0.34 Estimate, Sales $357.807M Beat $306.399M Estimate
PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.34 by 176.47 percent. This is a 370 percent increase over earnings of…
-
3 days ago benzinga.com
PTC Therapeutics Raises FY2026 Sales Guidance from $1.180B-$1.280B to $1.290B-$1.320B vs $1.262B Est
PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.180 billion-$1.280 billion to $1.290 billion-$1.320 billion vs $1.262 billion estimate.
3 days ago prnewswire.com
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with…
1 week ago zacks.com
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago defenseworld.net
PTC Therapeutics (NASDAQ:PTCT) Director Sells $149,025.00 in Stock
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) Director Michael Schmertzler sold 2,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price…
2 weeks ago prnewswire.com
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial…
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.
3 weeks ago defenseworld.net
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 435 Shares of Company Stock
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Boulding sold 435 shares of the company's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of…
3 weeks ago defenseworld.net
Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)
Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two…
1 month ago defenseworld.net
PTC Therapeutics (NASDAQ:PTCT) Shares Climb 4.7% – Here’s Why
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) shot up 4.7% during trading on Monday. The stock traded as high as $65.75 and last traded at $65.60. 659,183 shares were traded…
1 month ago prnewswire.com
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
-
1 month ago benzinga.com
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137
Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.
1 month ago prnewswire.com
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced…
1 month ago seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago defenseworld.net
Amundi Raises Holdings in PTC Therapeutics, Inc. $PTCT
Amundi grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 171.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…
1 month ago defenseworld.net
California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT
California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during the undefined quarter, according to the company in its most recent…
2 months ago prnewswire.com
PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare…
-
2 months ago benzinga.com
PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28
The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet…
2 months ago prnewswire.com
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – –…
2 months ago seekingalpha.com
PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential
PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven…
-
2 months ago benzinga.com
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.
2 months ago benzinga.com
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.
-
2 months ago benzinga.com
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.
-
2 months ago benzinga.com
PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals
Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy…
2 months ago benzinga.com
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104
Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.
-
3 months ago benzinga.com
PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est
PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion vs $1.196 billion estimate.
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.
-
3 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130
Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $124 to $130.
-
3 months ago benzinga.com
RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $85
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $82 to $85.
3 months ago benzinga.com
8 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
4 months ago benzinga.com
PTC Therapeutics Announces Proposed Private Placement Of $500M Of Convertible Senior Notes Due 2031
PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to $50.0 million of additional…
-
5 months ago benzinga.com
Jefferies Upgrades PTC Therapeutics to Buy, Raises Price Target to $85
Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $76 to $85.
-
5 months ago benzinga.com
TD Cowen Upgrades PTC Therapeutics to Buy, Raises Price Target to $90
TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $75 to $90.
-
5 months ago benzinga.com
RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $82
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $81 to $82.
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $95
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $86 to $95.
-
5 months ago benzinga.com
PTC Therapeutics Raises FY2026 Sales Guidance from $700.000M-$800.000M to $1.080B-$1.180B vs $1.013B Est
PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to $1.080 billion-$1.180 billion vs $1.013 billion estimate.
-
5 months ago benzinga.com
PTC Therapeutics Q1 EPS $(0.03) Beats $(0.48) Estimate, Sales $272.551M Beat $218.805M Estimate
PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.48) by 93.75 percent. This is a 100.3 percent decrease over earnings of…
6 months ago benzinga.com
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefits and stable safety signals.